Autolus (AUTL) director Ryan Richardson reports 80K-share option grant
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc director Ryan Richardson reported an initial holding of a share option covering 80,000 underlying American Depositary Shares. The option has an exercise price of $1.41 per share and expires on December 1, 2035. It vests in 36 equal monthly installments starting on January 1, 2026, meaning the right to buy the shares builds gradually over three years. This filing does not reflect a new stock purchase or sale, but discloses an existing equity award position.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Richardson Ryan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 80,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What does the Autolus (AUTL) Form 3 filed by Ryan Richardson show?
The Form 3 shows Ryan Richardson’s initial reported holding of a stock option for 80,000 underlying American Depositary Shares in Autolus. It establishes his baseline equity position as a director, with no indication of recent buying or selling activity.
What is the exercise price and term of Ryan Richardson’s Autolus (AUTL) option?
The option has an exercise price of $1.41 per American Depositary Share and expires on December 1, 2035. This defines the fixed price at which he may buy shares during the option’s life, assuming vesting conditions are met.
How does Ryan Richardson’s Autolus (AUTL) option vest over time?
The option vests in 36 equal monthly installments starting January 1, 2026. This means one‑thirty‑sixth of the 80,000 underlying American Depositary Shares becomes exercisable each month over three years, rather than all at once.
Does Ryan Richardson’s Autolus (AUTL) Form 3 indicate recent insider buying or selling?
No, the Form 3 reflects a holding entry rather than a new transaction. It discloses an existing share option award position and its terms, without reporting open‑market purchases, sales, or other buy/sell activity in Autolus shares.